Head and Neck Cancer

Gene Therapy Arrests Tumor Growth, Induces Apoptosis

Published in Gene Therapy Weekly, April 19th, 2001

Titan Pharmaceuticals, Inc. (TTP), announced results of a preclinical study that demonstrated effectiveness of Titan's RB94 cancer therapy in the treatment of an animal model of head and neck squamous cell carcinoma (HNSCC).

Data from this study demonstrated that RB94 caused growth arrest and induced apoptotic death in human tumor cells.

Additionally, the mechanisms of anti-tumor activity demonstrated by RB94 in these studies suggest potential for synergy with chemotherapy and radiation therapy in the treatment of cancer. These results were presented March 28, 2001, at the American Association of Cancer Research conference in New Orleans,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry